The present invention relates a fluidic device, particularly a microfluidic or nano-fluidic device, for electrochemical sensing of an analyte that is applied to the device.
G01N 27/00 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
G01N 27/403 - Ensembles de cellules et d'électrodes
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A microfluidic device for an optofluidic sensor, the device including a base with a planar surface, the planar surface having: a) an array of micropillars projecting from the planar surface forming an open spectral region; and b) a sample loading region configured to receive an analyte solution such that the analyte solution is in fluid contact with micropillars for dispersal of analyte solution from the sample loading region to the spectral region, wherein the micropillars are spaced to form interpillar microchannels, there being at least one active resonator, in the form of a whispering gallery mode (WGM) microsphere, immobilised between micropillars within a microchannel, such that analyte solution disperses about a microsphere in the spectral region and the microsphere produces a WGM modulated spectrum suitable for optical spectroscopy.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
A data storage medium for storing digital data. The medium includes a mixture of different nano-sized materials, each of the nano-sized materials having a respective optical transition profile characterizing an optical transition of the nano-sized material and covering a respective wavelength range, wherein a combined optical transition profile of the mixture covers an extended wavelength range as compared to the respective wavelength ranges of the respective optical transition profiles of the different nano-sized materials, and wherein one or more of the different nano-sized materials is photo-reactive to selectively vary a respective absorption/emission band upon irradiation to encode digital data in the combined optical transition profile of the mixture.
G11B 7/2533 - Supports d’enregistrement caractérisés par le choix du matériau des couches autres que les couches d'enregistrement de substrats comprenant des résines
4.
APPARATUS AND PROCESS FOR DEBITTERING OLIVES AND OLIVES OBTAINED THEREBY
The present disclosure relates to a process for debittering olives without intentional fermentation or lye treatment, the process comprising: providing at least one container loaded with olives; contacting an aqueous acidic brine with the olives under conditions sufficient to release at least some of any bitter compounds therefrom; and contacting the aqueous acidic brine with an adsorbent resin so as to remove one or more of any bitter compounds or colouring compounds from the aqueous acidic brine that has been in contact with the olives.
A23L 5/20 - Élimination de constituants indésirables, p. ex. désodorisation ou détoxication
C02F 1/42 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par échange d'ions
C02F 103/32 - Nature de l'eau, des eaux résiduaires ou des eaux ou boues d'égout à traiter provenant de l'industrie alimentaire, p. ex. eaux résiduaires de brasseries
5.
COMPOSITION FOR PREVENTING AND/OR TREATING METABOLIC DISORDERS AND METHOD OF ITS PREPARATION
The present disclosure relates to composition and methods for the treatment and prevention of metabolic diseases and disorders. According to a first aspect of the present invention, there is provided a composition for administration to a subject in need thereof comprising 1-99% (v/v) of an aqueous solution of at least 1% (w/v) inulin and/or one or more analogues thereof, and 1-99% (v/v) of a dispersed suspension of at least 1% (w/v) clay.
A mesoporous, hierarchically porous, and macroporous methacrylate-based polymer monoliths and preparation methods thereof through reversible addition-fragmentation chain-transfer (RAFT) polymerization is disclosed. The polymer monoliths may find use in liquid chromatography applications.
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ
C08J 9/28 - Mise en œuvre de substances macromoléculaires pour produire des matériaux ou objets poreux ou alvéolairesLeur post-traitement par élimination d'une phase liquide d'un objet ou d'une composition macromoléculaire, p. ex. par séchage du coagulum
7.
METHODS, PRODUCTS AND SYSTEMS FOR PROGNOSIS OF SUBJECTS SUFFERING FROM MULTIPLE MYELOMA
The present disclosure relates to methods, products and systems for the prognosis of subjects suffering from multiple myeloma. In certain embodiments, the present disclosure provides a method of prognosis for a subject suffering from multiple myeloma. The method comprises determining the level of desmoglein 2 (DSG2) in malignant plasma cells from the subject, wherein an increased level of DSG2 in the plasma cells is indicative of a poorer prognosis for the subject.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
8.
OVARIAN CANCER BIOMARKER DETECTION THROUGH OVARIAN BLOOD SAMPLING
The present invention is directed to a biological marker of ovarian cancer, including early stage ovarian cancer. Specifically, the present invention provides methods for detecting ovarian cancer in a subject which include detecting an expression level of the biological marker junction plakoglobin in blood of the subject. An expression level of junction plakoglobin that is higher than a reference expression level for junction plakoglobin indicates that the subject has ovarian cancer. Methods of identifying a subject having ovarian cancer and methods of determining if a subject is susceptible to developing ovarian cancer are also provided based on detecting the expression level of junction plakoglobin in blood of the subject. The present invention also extends to methods of treatment of ovarian cancer together with methods of screening a candidate therapeutic agent for use in treating ovarian cancer. Furthermore, compositions and kits for detecting ovarian cancer in a subject are provided, as well as a method of identifying a biomarker for a cancer, including ovarian cancer.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC (Australie)
Inventeur(s)
Ebert, Lisa, Michelle
Brown, Michael, Paul
Truong, Nga, Thi, Hong
Abrégé
The present invention provides methods, systems, and kits for determining responsiveness of a subject with or susceptible to cancer to anti-PD1 immune checkpoint inhibitor immunotherapy (ICII) comprising determining the level of one or more of markers CD15 in CD8+Ki67/CD71+ or CD8/CD4-Ki67/CD71+ T cells, CTLA-4 in CD4+Ki67/CD71+ T cells, FoxP3 in CD4+K167/CD71+ T cells, KI67 or CD71 in CD8+ T cells, wherein an increase in CD15, CTLA-4, FoxP3, or a decrease in KI67 or CD71 prior to immunotherapy is indicative that the subject is responsive to immunotherapy, particularly PD1 ICII.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Methods of potentiating chemotherapy or radiotherapy are disclosed. The methods comprise administering to a subject in need of chemotherapeutic or radiotherapeutic treatment an effective amount of a composition comprising biocompatible nanoparticles under conditions in which the nanoparticles alter one or more cell regulatory mechanisms in cells in which the nanoparticles are localised or other cells. Then one or more doses of a chemotherapeutic or radiotherapeutic treatment are administered to the subject either concurrently with or after the nanoparticles have altered the one or more cell regulatory mechanisms in the cells in which the nanoparticles are localised or other cells. Also disclosed are methods of enhancing the effects of chemotherapy or radiotherapy on a cell population, methods of increasing the amount of strand breaks in DNA in a cell, and methods of inducing cancer cell death.
The present invention relates generally to devices able to manipulate, process, treat, sort, measure and/or analyse samples at a micro level, commonly referred to as microfluidic devices. In particular, the present invention relates to a microfluidic device that can be used for the analysis of particulate samples, such as by the leaching at a micro level of a crushed rock particulate sample from a mineral ore body and the subsequent analysis of the leachate. The present invention also relates to a method for the use of a microfluidic device for the analysis of a particulate sample.
Drug delivery systems are needed to assist in improving the therapeutic characteristics of pharmaceutical agents. Provided is a dry composition, comprising a polysaccharide, such as inulin, and lipid droplets, wherein the lipid droplets are encapsulated within polymeric chains of the polysaccharide, and wherein the polysaccharide is not in a nano -particulate form. The use of such compositions enables efficient delivery of agents, such as poorly-water soluble drugs and antibiotics.
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
A61K 31/366 - Lactones ayant des cycles à six chaînons, p. ex. delta-lactones
A61K 38/14 - Peptides contenant des radicaux saccharideLeurs dérivés
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
The present invention relates to antimicrobial compositions and methods for their use. In particular, the compositions comprise an antimicrobial agent and a nanostructured liquid crystal carrier, wherein the antimicrobial agent is contained within the nanostructured liquid crystal carrier, and wherein the nanostructured liquid crystal carrier potentiates the activity of the antimicrobial agent. Antimicrobial agents encompassed by the present invention include cationic antibiotics, antimicrobial peptides, and antifungal agents. Nanostructured liquid crystal carriers encompassed by the present invention include those formed from an amphiphilic lipid such as monoolein and phytantriol. Antimicrobial compositions encompassed by the present invention can be used for the treatment or prevention of a microbial infection, such as that caused by a Gram-negative bacterium, including where the microbial infection forms part of a biofilm. The present invention also relates to methods for reducing the viability of a microorganisms, for potentiating the activity of an antimicrobial agent, for reducing the dose of an antimicrobial agent required to treat or prevent a microbial infection, or for increasing the potency of an antimicrobial agent required to treat or prevent a microbial infection, by administering an antimicrobial composition described herein. Kits comprising the antimicrobial compositions are also encompassed by the present invention.
A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p. ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
MALAYSIA AUTOMOTIVE ROBOTICS AND IOT INSTITUTE (Malaisie)
Inventeur(s)
Jane, Marta Llusca
Pajak, Aleksandra
Zuber, Kamil
Switalska, Eliza
Murphy, Peter J.
Abrégé
The present disclosure relates to coated articles with a low-E coating and their preparation methods. The coated article comprises a low-E coating which is supported by a substrate and comprises a metallic IR reflective layer, a protective layer in contact with the metallic IR reflective layer, and a dielectric layer
C23C 28/00 - Revêtement pour obtenir au moins deux couches superposées, soit par des procédés non prévus dans un seul des groupes principaux , soit par des combinaisons de procédés prévus dans les sous-classes et
C03C 17/36 - Traitement de surface du verre, p. ex. du verre dévitrifié, autre que sous forme de fibres ou de filaments, par revêtement avec au moins deux revêtements ayant des compositions différentes un revêtement au moins étant un métal
C23C 14/35 - Pulvérisation cathodique par application d'un champ magnétique, p. ex. pulvérisation au moyen d'un magnétron
MALAYSIA AUTOMOTIVE ROBOTICS AND IOT INSTITUTE (Malaisie)
Inventeur(s)
Yunos, Luqman
Jane, Marta Llusca
Murphy, Peter J.
Zuber, Kamil
Abrégé
The present disclosure relates to coated articles and their preparation methods. The coated article comprises a metallic layer, wherein the metallic layer bears a frequency selective surface configured to reduce attenuation of telecommunication frequency signal transmission.
C03C 17/36 - Traitement de surface du verre, p. ex. du verre dévitrifié, autre que sous forme de fibres ou de filaments, par revêtement avec au moins deux revêtements ayant des compositions différentes un revêtement au moins étant un métal
C23C 14/35 - Pulvérisation cathodique par application d'un champ magnétique, p. ex. pulvérisation au moyen d'un magnétron
C23C 28/00 - Revêtement pour obtenir au moins deux couches superposées, soit par des procédés non prévus dans un seul des groupes principaux , soit par des combinaisons de procédés prévus dans les sous-classes et
A method for producing a porous copolymer monolith substrate for use in flow through liquid chromatography applications is disclosed. The method comprises forming a reaction composition comprising at least one monoethylenically unsaturated aryl monomer, at least one polyethylenically unsaturated aryl monomer, a RAFT agent, at least one liquid porogen, and a radical initiator. The reaction composition is introduced to a mold having a shape and dimensions suitable for forming a liquid chromatography substrate. The monoethylenically unsaturated aryl monomer, the polyethylenically unsaturated aryl monomer and the RAFT agent are copolymerised in the mold under conditions to form a solid copolymer network that is phase-separated from the reaction composition and/or any liquid components.
B01J 20/285 - Absorbants ou adsorbants poreux à base de polymères
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
The present disclosure relates to a novel compound, which is an analogue of vitamin D. The present disclosure also relates to pharmaceutical compositions including the novel compound, and to the use of the novel compound in treating and/or preventing disorders associated with low vitamin D levels, particularly disorders that respond to the inhibition of the CYP24A1 enzyme.
C07C 401/00 - Produits d'irradiation du cholestérol ou de ses dérivésDérivés de vitamine D, séco-9,10 cyclopenta[a]phénanthrène ou leurs analogues obtenus par préparation chimique sans irradiation
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/592 - Dérivés du 9,10-séco-ergostane, p. ex. ergocalciférol, vitamine D2
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 3/02 - Nutriments, p. ex. vitamines, minéraux
A computer-implemented data processing method to improve information quality in data sequences by attenuating noise in the data sequences, the method including: receiving input data sequences, having a plurality of elements, from one or more sensors, each of the elements having at least one dimensional component; performing a spectral analysis on the dimensional component of each of the elements, independently, to estimate a signal profile of the input data sequences; estimating a noise profile of the input data sequences using calibration data associated with the sensor; dynamically calculating a time-constant for a noise attenuation filter, and adapting the time-constant over time, for each one of the elements in the input data sequences, based on the relationship between the noise profile and the signal profile; applying the noise attenuation filter for each one of the elements to each one of the elements, respectively, to filter the input data sequences to derive filtered data sequences; and outputting the filtered data sequences.
Disclosed herein is a plasma treatment method comprising: providing a plasma source and a screen comprising a hydrogel and positioning the screen between the plasma source and a surface of a target to be treated with the plasma such that substantially all of the plasma from the plasma source passes through the screen prior to contacting the surface of the target and the screen reduces the concentration of one or more species from the plasma; and/or contacting a surface of a target to be treated with the gel composition comprising a gel forming material and a liquid phase comprising plasma activated liquid.
The present disclosure relates to a water distillation apparatus comprising a transparent housing substantially encasing a photothermal substrate and a condensing surface; a photothermal substrate comprising a hydrophilic and porous photothermal material capable of generating heat upon exposure to sunlight, the photothermal substrate having an upper end and a lower end; a condensing surface being spaced from the photothermal substrate; a water feeder in fluid contact with the upper end of the photothermal substrate, and configured to introduce a feed aqueous solution to the photothermal substrate such that the feed aqueous solution is continuously fed to the upper end and moves to the lower end of the photothermal substrate; wherein heat generated by the photothermal material evaporates water from the photothermal substrate to generate steam which condenses on the condensing surface to form condensate; a condensate collector positioned at a lower end of the transparent housing and configured to collect condensate that runs down the condensing surface.
B32B 27/10 - Produits stratifiés composés essentiellement de résine synthétique comme seul composant ou composant principal d'une couche adjacente à une autre couche d'une substance spécifique de papier ou de carton
B32B 27/30 - Produits stratifiés composés essentiellement de résine synthétique comprenant une résine vinyliqueProduits stratifiés composés essentiellement de résine synthétique comprenant une résine acrylique
C02F 103/08 - Eau de mer, p. ex. pour le dessalement
CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC (Australie)
UNIVERSITY OF SOUTH AUSTRALIA (Australie)
THE UNIVERSITY OF ADELAIDE (Australie)
Inventeur(s)
Tvorogov, Denis
Lopez, Angel
Thomas, Daniel
Abrégé
The present invention relates generally to methods for preventing and/or treating myeloproliferative disorders. More specifically, the myeloproliferative disorders are those associated with the presence of a frameshift mutation in the calreticulin (CALR) gene of a cell involved in the myeloproliferative disorders. The present invention also relates to immunological agents, such as antibodies, to calreticulin, methods for preventing and/or treating myeloproliferative diseases using the immunological agents, and chimeric antigen receptors having extracellular domains based on antibodies to calreticulin.
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
22.
PHOTOTHERMAL EVAPORATION DEVICES AND METHODS FOR ENHANCING PHOTOTHERMAL EVAPORATION PERFORMANCE
The present disclosure relates to a solar-driven interfacial evaporation device and a method of improving the evaporation rate of water through solar-driven interfacial evaporation.
The present disclosure relates to a process for debittering olives without intentional fermentation or lye treatment, the process comprising: providing at least one container loaded with olives; contacting an aqueous acidic brine with the olives under conditions sufficient to release at least some of any bitter compounds therefrom; and contacting the aqueous acidic brine with an adsorbent resin so as to remove one or more of any bitter compounds or colouring compounds from the aqueous acidic brine that has been in contact with the olives.
C02F 1/42 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par échange d'ions
C02F 103/32 - Nature de l'eau, des eaux résiduaires ou des eaux ou boues d'égout à traiter provenant de l'industrie alimentaire, p. ex. eaux résiduaires de brasseries
A23L 5/20 - Élimination de constituants indésirables, p. ex. désodorisation ou détoxication
A data storage medium for storing digital data is disclosed. The medium comprises a mixture of different nano-sized materials, each of the nano-sized materials having a respective optical transition profile characterizing an optical transition of the nano-sized material and covering a respective wavelength range, wherein a combined optical transition profile of the mixture covers an extended wavelength range as compared to the respective wavelength ranges of the respective optical transition profiles of the different nano-sized materials, and wherein one or more of the different nano-sized materials is photo-reactive to selectively vary a respective absorption/emission band upon irradiation to encode digital data in the combined optical transition profile of the mixture.
B82B 1/00 - Nanostructures formées par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
B82B 3/00 - Fabrication ou traitement des nanostructures par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p. ex. calcul quantique ou logique à un électron
G01N 21/25 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes
G01N 21/63 - Systèmes dans lesquels le matériau analysé est excité de façon à ce qu'il émette de la lumière ou qu'il produise un changement de la longueur d'onde de la lumière incidente excité optiquement
G02B 1/02 - Éléments optiques caractérisés par la substance dont ils sont faitsRevêtements optiques pour éléments optiques faits de cristaux, p. ex. sel gemme, semi-conducteurs
G02F 1/00 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire
C09K 11/77 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant des métaux des terres rares
G02F 1/355 - Optique non linéaire caractérisée par les matériaux utilisés
G11B 7/243 - Supports d’enregistrement caractérisés par le choix du matériau des couches d'enregistrement comportant seulement des matériaux inorganiques, p. ex. des couches ablatives
G11C 13/04 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage non couverts par les groupes , ou utilisant des éléments optiques
Provided is an apparatus for inducing and/or controlling flow of a fluid within a microchannel in a microfluidic device. The apparatus includes a fluid reservoir configured for holding a volume of fluid to be transported through said microfluidic channel and also configured for fluid connection to an inlet of said microfluidic channel. The apparatus also includes an evaporation reservoir configured for fluid connection to an outlet of said microfluidic channel. The evaporation reservoir includes at least one wetting, wicking or hydrophilic structure positioned at least partly within the reservoir. The wetting, wicking, or hydrophilic structure is capable of absorbing or conducting a fluid present in the microfluidic channel via wicking action or capillary force and maintaining a substantially constant volume of fluid in the evaporation reservoir. In use, evaporation of fluid at the outlet results in fluid being drawn from the fluid reservoir through the microfluidic channel to thereby create a flow of the fluid in the microfluidic channel.
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
26.
Microfluidic Sensor for Continuous or Semi-Continuous Monitoring of Quality of an Aqueous Solution
The present disclosure relates to a microfluidic device for measuring one or more parameters in a fluid sample, which includes a sample microfluidic channel disposed on a solid substrate, a reagent microfluidic channel disposed on a solid substrate, a mixing microfluidic channel disposed on a solid substrate, and an optical reading window located downstream of the mixing microfluidic channel, through which a response indicative of the parameter(s) change can be measured optically. The present disclosure also relates to an apparatus for measuring one or more parameters in a fluid sample which includes the microfluidic device as well as a method for measuring one or more parameters in a fluid sample through the device or the apparatus.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
F04B 19/00 - "Machines" ou pompes ayant des caractéristiques particulières non prévues dans les groupes ou présentant un intérêt autre que celui visé par ces groupes
in-situin-situin-situ process for soil remediation. The remediation apparatus comprises: (a) at least one fluid capillary channel configured to draw in and transport an aqueous fluid from a contaminated soil by capillary action when in contact with the contaminated soil; and (b) a solar absorber comprising a photothermal material loaded on a porous material, the solar absorber in fluid connection with the at least one fluid capillary channel and configured to generate heat under solar irradiation so as to accelerate evaporation of the aqueous fluid from the apparatus, wherein at least some of any contaminants from the contaminated soil that are drawn into the apparatus in the aqueous fluid are retained in the apparatus.
ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (Australie)
UNIVERSITY OF SOUTH AUSTRALIA (Australie)
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF (Irlande)
MONASH UNIVERSITY (Australie)
Inventeur(s)
Selemidis, Stavros
Brooks, Doug A.
O'Leary, John
Abrégé
The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Methods for detecting a prostate cancer in a subject comprise detecting a marker selected from an endosomal associated marker and/or a lysosomal associated marker from the subject.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
There is a need to provide a system for culturing cells or cell clusters, such as organoids, whereby the location of the cell, or cell cluster, is fixed within the culture system. This permits easy localisation of an individual cell or cell cluster. Preferably, this is done in a manner that still allows for development of the cell or cell cluster in a biologically accurate way and can be readily used with high-throughput liquid handling techniques and analysis techniques, such as microscopy. This may be addressed by providing a cell culture insert, which provides a suspended cell growth platform which allows a cell, or cell cluster, to be cultured in an inverted position at a predetermined distance from the bottom of a cell culture plate.
CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC (Australie)
THE UNIVERSITY OF ADELAIDE (Australie)
Inventeur(s)
Wallington-Beddoe, Craig, Thomas
Bonder, Claudine, Sharon
Ebert, Lisa, Michelle
Abrégé
The present disclosure relates to methods, products and systems for the prognosis of subjects suffering from multiple myeloma. In certain embodiments, the present disclosure provides a method of prognosis for a subject suffering from multiple myeloma. The method comprises determining the level of desmoglein 2 (DSG2) in malignant plasma cells from the subject, wherein an increased level of DSG2 in the plasma cells is indicative of a poorer prognosis for the subject.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
The present invention relates to antimicrobial compositions and methods for their use. In particular, the compositions comprise an antimicrobial agent and a nanostructured liquid crystal carrier, wherein the antimicrobial agent is contained within the nanostructured liquid crystal carrier, and wherein the nanostructured liquid crystal carrier potentiates the activity of the antimicrobial agent. Antimicrobial agents encompassed by the present invention include cationic antibiotics, antimicrobial peptides, and antifungal agents. Nanostructured liquid crystal carriers encompassed by the present invention include those formed from an amphiphilic lipid such as monoolein and phytantriol. Antimicrobial compositions encompassed by the present invention can be used for the treatment or prevention of a microbial infection, such as that caused by a Gram-negative bacterium, including where the microbial infection forms part of a biofilm. The present invention also relates to methods for reducing the viability of a microorganisms, for potentiating the activity of an antimicrobial agent, for reducing the dose of an antimicrobial agent required to treat or prevent a microbial infection, or for increasing the potency of an antimicrobial agent required to treat or prevent a microbial infection, by administering an antimicrobial composition described herein. Kits comprising the antimicrobial compositions are also encompassed by the present invention.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p. ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
A61L 2/00 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/08 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'oxygène
33.
MICROFLUIDIC DEVICE AND METHOD FOR ANALYSIS OF A PARTICULATE SAMPLE
The present invention relates generally to devices able to manipulate, process, treat, sort, measure and/or analyse samples at a micro level, commonly referred to as microfluidic devices. In particular, the present invention relates to a microfluidic device that can be used for the analysis of particulate samples, such as by the leaching at a micro level of a crushed rock particulate sample from a mineral ore body and the subsequent analysis of the leachate. The present invention also relates to a method for the use of a microfluidic device for the analysis of a particulate sample.
The present invention relates generally to devices able to manipulate, process, treat, sort, measure and/or analyse samples at a micro level, commonly referred to as microfluidic devices. In particular, the present invention relates to a microfluidic device that can be used for the analysis of particulate samples, such as by the leaching at a micro level of a crushed rock particulate sample from a mineral ore body and the subsequent analysis of the leachate. The present invention also relates to a method for the use of a microfluidic device for the analysis of a particulate sample.
A method for producing a porous copolymer monolith substrate for use in flow through liquid chromatography applications is disclosed. The method comprises forming a reaction composition comprising at least one monoethylenically unsaturated aryl monomer, at least one polyethylenically unsaturated aryl monomer, a RAFT agent, at least one liquid porogen, and a radical initiator. The reaction composition is introduced to a mold having a shape and dimensions suitable for forming a liquid chromatography substrate. The monoethylenically unsaturated aryl monomer, the polyethylenically unsaturated aryl monomer and the RAFT agent are copolymerised in the mold under conditions to form a solid copolymer network that is phase-separated from the reaction composition and/or any liquid components.
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
B01J 20/285 - Absorbants ou adsorbants poreux à base de polymères
C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ
C08J 9/28 - Mise en œuvre de substances macromoléculaires pour produire des matériaux ou objets poreux ou alvéolairesLeur post-traitement par élimination d'une phase liquide d'un objet ou d'une composition macromoléculaire, p. ex. par séchage du coagulum
B01D 15/22 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives à la structure de la colonne
Methods and uses of Rilpivirine and analogues thereof in the treatment and/or prevention of proliferative cell diseases and conditions are disclosed. Among the diseases and conditions that may be treated and/or prevented, are cancers characterised by Aurora A dysregulation.
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A computer-implemented data processing method to improve information quality in data sequences by attenuating noise in the data sequences, the method including: receiving input data sequences, having a plurality of elements, from one or more sensors, each of the elements having at least one dimensional component; performing a spectral analysis on the dimensional component of each of the elements, independently, to estimate a signal profile of the input data sequences; estimating a noise profile of the input data sequences using calibration data associated with the sensor; dynamically calculating a time-constant for a noise attenuation filter, and adapting the time-constant over time, for each one of the elements in the input data sequences, based on the relationship between the noise profile and the signal profile; applying the noise attenuation filter for each one of the elements to each one of the elements, respectively, to filter the input data sequences to derive filtered data sequences; and outputting the filtered data sequences.
G10K 11/178 - Procédés ou dispositifs de protection contre le bruit ou les autres ondes acoustiques ou pour amortir ceux-ci, en général utilisant des effets d'interférenceMasquage du son par régénération électro-acoustique en opposition de phase des ondes acoustiques originales
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Educational services; university education services; higher
education services; adult education services; provision of
educational courses; conducting of educational courses;
education academy services; educational instruction;
educational assessment services; provision of educational
examinations; provision of educational information;
publication of educational materials; dissemination of
educational material; provision of education services via an
online forum.
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Educational services, namely, conducting classes, seminars, conferences, workshops, at the university level; university education services, namely, education services in the nature of courses at the university level; higher education services, namely, providing courses of instruction at the university level; education academy services, namely, providing courses of instruction at the university level; educational instruction, namely, providing courses of instruction at the university level; providing educational assessment services; provision of educational examinations, namely, educational examination services; provision of educational information, namely, providing information relating to higher education services; publication of educational materials in the nature of texts, books, journals; provision of education services via an online forum, namely, providing on-line classes, seminars, workshops at the university level
40.
OVARIAN CANCER BIOMARKER DETECTION THROUGH OVARIAN BLOOD SAMPLING
The present invention is directed to a biological marker of ovarian cancer, including early stage ovarian cancer. Specifically, the present invention provides methods for detecting ovarian cancer in a subject which include detecting an expression level of the biological marker junction plakoglobin in blood of the subject. An expression level of junction plakoglobin that is higher than a reference expression level for junction plakoglobin indicates that the subject has ovarian cancer. Methods of identifying a subject having ovarian cancer and methods of determining if a subject is susceptible to developing ovarian cancer are also provided based on detecting the expression level of junction plakoglobin in blood of the subject. The present invention also extends to methods of treatment of ovarian cancer together with methods of screening a candidate therapeutic agent for use in treating ovarian cancer. Furthermore, compositions and kits for detecting ovarian cancer in a subject are provided, as well as a method of identifying a biomarker for a cancer, including ovarian cancer.
An apparatus for inducing and/or controlling flow of a fluid within a microchannel in a microfluidic device. The apparatus comprises a fluid reservoir configured for holding a volume of fluid to be transported through said microfluidic channel and also configured for fluid connection to an inlet of said microfluidic channel. The apparatus also comprises an evaporation reservoir configured for fluid connection to an outlet of said microfluidic channel. The evaporation reservoir comprises at least one wetting, wi eking or hydrophilic structure positioned at least partly within the reservoir. The wetting, wicking, or hydrophilic structure is capable of absorbing or conducting a fluid present in the microfluidic channel via wicking action or capillary force and maintaining a substantially constant volume of fluid in the evaporation reservoir. In use, evaporation of fluid at the outlet results in fluid being drawn from the fluid reservoir through the microfluidic channel to thereby create a flow of the fluid in the microfluidic channel.
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
42.
MICROFLUIDIC SENSOR FOR CONTINUOUS OR SEMI-CONTINUOUS MONITORING OF QUALITY OF AN AQUEOUS SOLUTION
The present disclosure relates to a microfluidic device for measuring one or more parameters in a fluid sample, which comprises a sample microfluidic channel disposed on a solid substrate, a reagent microfluidic channel disposed on a solid substrate, a mixing microfluidic channel disposed on a solid substrate, and an optical reading window located downstream of the mixing microfluidic channel, through which a response indicative of the parameter! s) change can be measured optically. The present disclosure also relates to an apparatus for measuring one or more parameters in a fluid sample which comprises the microfluidic device as well as a method for measuring one or more parameters in a fluid sample through the device or the apparatus.
G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
A method of selective capturing target prostate cancer cells or target prostate cancer cell-derived exosomes from urine or a urine derived fluid is disclosed. The method comprises providing a sample of urine or a urine derived fluid; providing a substrate having one or more cell capture surface, each cell capture surface comprising one or more prostate cancer cell or exosome selective binding agent capable of binding one or more target prostate cancer cell or target prostate cancer cell-derived exosome; and contacting the sample of urine or a urine derived fluid with the one or more cell capture surface under conditions to bind at least some of the target prostate cancer cells or target prostate cancer cell-derived exosomes from the urine (if present) to the cell capture surface.
A microfluidic device for extraction of one or more target soluble component from a complex sample matrix is disclosed. The device comprises a substrate and a collector solution path disposed within the substrate. The collector solution path comprises a collector microfluidic channel configured for flow of a collector solution therein, an inlet port on a surface of the substrate and in fluidic contact with the collector microfluidic channel for introducing the collector solution to the collector microfluidic channel, and an outlet port on a surface of the substrate and in fluidic contact with the collector microfluidic channel for removing the collector solution from the collector microfluidic channel. The device also comprises a slit channel disposed within the substrate and configured so that is can be brought into fluidic contact with the complex sample matrix to be sampled and prevent ingress of at least some of any non¬ soluble matter present in the complex sample matrix into the collector solution path.
B01D 29/17 - Éléments filtrants avec des supports agencés pour la filtration à courant dirigé vers l'intérieur à extrémités ouvertes
B01D 29/33 - Éléments filtrants autoportants agencés pour la filtration à courant dirigé vers l'intérieur
B01D 29/37 - Éléments filtrants autoportants à extrémités ouvertes
B01D 29/92 - Filtres à éléments filtrants stationnaires pendant la filtration, p. ex. filtres à aspiration ou à pression, non couverts par les groupes Leurs éléments filtrants comportant des dispositifs d'alimentation ou d'évacuation d'évacuation du filtrat
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
B81B 1/00 - Dispositifs sans éléments mobiles ou flexibles, p. ex. dispositifs capillaires microscopiques
ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (Australie)
UNIVERSITY OF SOUTH AUSTRALIA (Australie)
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEEN ELIZABETH NEAR DUBLIN (Irlande)
MONASH UNIVERSITY (Australie)
Inventeur(s)
Selemidis, Stavros
Brooks, Doug A.
O'Leary, John
Abrégé
The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
THE FLINDERS UNIVERSITY OF SOUTH AUSTRALIA (Australie)
UNIVERSITY OF SOUTH AUSTRALIA (Australie)
Inventeur(s)
Chalker, Justin
Hayball, John, Dominic
Plush, Sally
Sweetman, Martin, Jay
Abrégé
The present disclosure relates to sorbent compositions, their use for adsorption of agents, and to products using the sorbent compositions. In certain embodiments, the present disclosure provides a sorbent composition comprising an activated carbon and a polysulfide polymer formed from an unsaturated cross-linker. Other embodiments are described.
B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone libreCompositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
C02F 1/28 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par absorption ou adsorption
B01D 15/08 - Adsorption sélective, p. ex. chromatographie
B01D 53/02 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p. ex. chromatographie préparatoire en phase gazeuse
47.
DEVICES AND METHODS FOR COLLECTING AND STORING FLUID SAMPLES FOR ANALYSIS
A sampling device for collecting, storing and processing fluid samples for analysis is disclosed. The sampling device comprises a porous polymer monolith sampling substrate housed within a substantially impermeable housing. The housing surrounds the sampling substrate and further comprises a sampling aperture via which the sampling substrate is accessible externally from the sampling device.
A teleconferencing system for providing remote assistance comprises a local user apparatus that captures both the field of view of the local user along with physiological state of the local user, and a remote user apparatus to allow the remote user to view what the local user is seeing and doing. The local user and remote user have a shared view and a shared audio link, and the remote user can provided assistance to the local user in performing tasks at the local site. Additionally the physiological state of the local user is monitored, and from the physiological state data, an estimate of the emotional state or physiological state of the local user is provided to the remote user. The remote user can interact or assist the local user, including controlling the amount and/or type of assistance provided to the local user based on their current emotional state.
A method of isolating fetal trophoblastic cells from a suitable biological sample is disclosed. The method comprises: providing a suitable biological sample comprising fetal trophoblastic cell population within a population of other cell types; enriching the fetal trophoblastic cell population by applying the biological sample to an inertial microfluidic device to separate fetal trophoblastic cells from the population of other cell types to obtain an enriched fetal trophoblast cell population; and collecting isolated fetal trophoblast cells by applying the enriched fetal trophoblast cell population to an array of microwells to collect isolated fetal trophoblast cells.
C12N 5/073 - Cellules ou tissus embryonnairesCellules fœtales ou tissus fœtaux
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
50.
Apparatus and method for anion detection and/or measurement
An apparatus for selectively detecting an anion in a medium and/or selectively measuring the concentration of an anion in a medium. The apparatus comprises at least one sensor and a conductive polymer film and is configured such that dielectric and/or electric property changes of the conductive polymer film can be detected by the sensor when the conductive polymer film is in hydraulic contact with the medium or after it has been in hydraulic contact with the medium. Methods of selectively detecting an anion in a medium and/or selectively determining a concentration of an anion in a medium are also provided.
G01N 27/22 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la capacité
G01N 27/12 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de l'absorption d'un fluideRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de la réaction avec un fluide
A novel class of inhibitors of protein kinases useful in the treatment of proliferative cell diseases and conditions including cancers, and especially those characterised by over-expression of CDK8 and/or one or more aberrant CDK8 activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure I.
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
Methods of potentiating chemotherapy or radiotherapy are disclosed. The methods comprise administering to a subject in need of chemotherapeutic or radiotherapeutic treatment an effective amount of a composition comprising biocompatible nanoparticles, particularly gold nanoparticles, under conditions in which the nanoparticles alter one or more cell regulatory mechanisms in cells in which the nanoparticles are localised or other cells. Then one or more doses of a chemotherapeutic or radiotherapeutic treatment are administered to the subject either concurrently with or after the nanoparticles have altered the one or more cell regulatory mechanisms in the cells in which the nanoparticles are localised or other cells. Also disclosed are methods of enhancing the effects of chemotherapy or radiotherapy on a cell population, methods of increasing the amount of strand breaks in DNA in a cell, and methods of inducing cancer cell death.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
The present disclosure relates to medical devices using coated polymers, methods for reducing platelet attachment and/or fouling associated with medical devices, and methods for coating polymers. Certain embodiments of the present disclosure provide a medical device comprising one or more polymeric materials coated with a hyperbranched polyglycerol.
C09D 171/08 - Polyéthers dérivés de composés hydroxylés ou de leurs dérivés métalliques
A61L 33/00 - Traitement antithrombogénique d'articles chirurgicaux, p. ex. de sutures, cathéters, prothèses ou d'articles pour la manipulation ou le conditionnement du sangMatériaux pour un tel traitement
C08G 65/22 - Éthers cycliques possédant en dehors du cycle au moins un atome autre que le carbone et l'hydrogène
A61L 31/06 - Matériaux macromoléculaires obtenus autrement que par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
54.
METHODS AND MARKERS FOR ASSESSING CANCER PROGRESSION
CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC. (Australie)
MONASH UNIVERSITY (Australie)
Inventeur(s)
Khew-Goodall, Yeesim
Belle, Leila
Ionic, Ana
Daly, Roger
Abrégé
The present disclosure relates to methods and markers for assessing cancer progression. In certain embodiments, the present disclosure provides a method of assessing progression of a cancer disease associated with increased or undesired receptor tyrosine kinase activity, the method comprising assessing endosomal recycling of the receptor tyrosine kinase mediated by phosphorylated PKCΔ associated with the cancer disease, wherein increased endosomal recycling of the receptor tyrosine kinase is indicative of progression of the cancer disease from a less progressed stage to a more progressed stage.
The present invention relates to antimicrobial compositions and methods for their use. In particular, the compositions comprise a glycerolipid, such as Capmul MCM, Imwitor 742, or Imwitor 988, and an antimicrobial agent, wherein the glycerolipid potentiates the activity of the antimicrobial agent. Antimicrobial agents encompassed by the present invention include antibiotics, antiseptics, and antifungals. Antimicrobial compositions encompassed by the present invention can be used for the treatment or prevention of an infection, such as a bacterial or fungal infection, or for reducing the viability of a microorganism, such as a bacterium. The present invention also relates to methods for potentiating the activity of an antimicrobial agent, for reducing the dose of an antimicrobial agent required to treat or prevent an infection, or for increasing the potency of an antimicrobial agent required to treat or prevent an infection, by administering an antimicrobial composition described herein. Kits comprising the antimicrobial compositions are also encompassed by the present invention.
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 31/546 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine contenant d'autres hétérocycles, p. ex. céphalotine
A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p. ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
A61K 38/14 - Peptides contenant des radicaux saccharideLeurs dérivés
A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p. ex. kétorolac, physostigmine
A microfluidic device for measuring an amount of an oxidant in a solution is disclosed. The device includes a microfluidic substrate configured to mix a solution sample to be analysed with an indicator dye solution containing an indicator dye under conditions suitable for some of the indicator dye to react with any oxidant in the solution to produce an oxidant measurement solution having a reduced indicator dye concentration that is indicative of the amount of oxidant in the solution, the microfluidic substrate including an optical reading window through which the reduced indicator dye concentration in the oxidant measurement solution can be measured optically.
G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
A solid phase microextraction substrate is disclosed. The solid phase microextraction substrate has a sorbent coating on at least part of a surface thereof. The coating is adapted for extracting at least one analyte component from a fluid matrix. The coating comprises sorbent particles in a polymeric adhesive matrix. A majority of pores in each sorbent particle in the coating do not contain substantially any of the polymeric adhesive matrices.
A solid phase microextraction substrate is disclosed. The solid phase microextraction substrate has a sorbent coating on at least part of a surface thereof. The coating is adapted for extracting at least one analyte component from a fluid matrix. The coating comprises sorbent particles in a polymeric adhesive matrix. A majority of pores in each sorbent particle in the coating do not contain substantially any of the polymeric adhesive matrices.
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (Irlande)
ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (Australie)
UNIVERSITY OF SOUTH AUSTRALIA (Australie)
MONASH UNIVERSITY (Australie)
Inventeur(s)
Selemidis, Stavros
Brooks, Doug A
O'Leary, John
Abrégé
The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation.Pharmaceutical compositions are also enabled herein.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
HORTICULTURE INNOVATION AUSTRALIA LIMITED (Australie)
Inventeur(s)
Fielke, John
Abrégé
The present disclosure relates to an apparatus and a method for hulling and/or shelling a crop of nuts and/or seeds or the like. In one aspect, the apparatus comprises a tubular, elongate conduit comprising a plurality of bends and a plurality of substantially vertically extending portions connected by at least some of the bends, the apparatus further comprising a means for establishing a fluid flow through the conduit sufficient to entrain at least one nut and/or seed and convey the or each of the nuts and/or seeds through the conduit so that these are involved in one or more collisions with and/or within the conduit as they pass therethrough. In one form, the conduit is comprised of a plurality of conduit modules which are joined together to cooperatively form the conduit.
FLINDERS UNIVERSITY OF SOUTH AUSTRALIA (Australie)
Inventeur(s)
Vasilev, Krasimir Atanasov
Macgregor, Melanie
Gleadle, Jonathan
Li, Jordan
Abrégé
A device for selective capture of target bladder cancer cells from urine or a urine derived fluid is provided. The device comprises a substrate having one or more cell capture surfaces, each cell capture surface comprising a functionalized film on the substrate and one or more target bladder cancer cell selective binding agents covalently bound to the functionalized film.
A substrate for sustaining isolated cells, tissues and/or organs is disclosed. The substrate sustains isolated cells, tissues and/or organs by supplying oxygen thereto. The substrate comprises at least one exposed surface comprising an oxygen generating material capable of chemically generating oxygen upon contact with water and a water and oxygen permeable membrane substantially covering the or each exposed surface.
B32B 5/18 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par le fait qu'une des couches contient un matériau sous forme de mousse ou essentiellement poreux
63.
ANTIBODY CONJUGATE FOR TREATING AND DETECTING BLADDER CANCER
CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC. (Australie)
SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES SANTE ET HUMAINES S.E.C. (Canada)
Inventeur(s)
Leyton, Jeffrey, Victor
Marsault, Eric
Beaudoin, Simon
Boudreault, Pierre-Luc
Bonin, Marc-André
Lopez, Angel
Abrégé
The present description relates to a conjugated anti-interleukin-5 receptor α-subunit (IL-5Rα) compound comprising cholic acid (ChAc) or a variant thereof, the ChAc conjugated to a non-cell penetrating peptide comprising a nuclear localization sequence (NLS) conjugated to an anti-interleukin-5 receptor α-subunit (IL-5Rα) compound and further conjugated to chemotherapeutic agent and/or a radionuclide.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 14/025 - Papovaviridae, p. ex. virus du papillome, virus du polyome, SV40, virus BK, virus JC
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
64.
AN OPTICAL PLURAL-COMB GENERATOR, A METHOD OF GENERATING AN OPTICAL PLURAL COMB, AND A PLURALITY OF MODE LOCKED LASERS THAT ARE MECHANICALLY COUPLED AND OPTICALLY INDEPENDENT
Disclosed herein is an optical plural-comb generator (10). The optical plural-comb generator (10) comprises a plurality of mode-locked lasers (12,14) that are mechanically coupled and optically independent. The optical plural-comb generator comprises an optical combiner (15) optically coupled to an output of each of the plurality of mode-locked lasers (12, 14) for combining a plurality of optical combs (20, 22) when generated by the plurality of mode-locked lasers (12,14).
A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure (I).
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A surgical depth guide comprising a body (2) adapted to cooperate with a passing pin to form a depth guide assembly, and wherein the body is unitary, or comprises a single piece. In one form, the body is generally elongate and comprises a guide portion (4) at a first end of the body, a first handle portion (8) hingedly connected to the guide portion, a second handle portion (6) hingedly connected to the first handle portion, and a gauge portion (10) hingedly connected to the second handle portion at a second end of the body. In a further aspect, there is provided a method for assembling the surgical depth guide assembly. In one form, the method comprises the steps of forming the body into a loop by slidably engaging the gauge portion (10) with the guide portion (4), and then securing the passing pin to the gauge portion.
The present invention relates to a drug delivery system and uses thereof. Specifically, a system that can be used to deliver therapeutic proteins, including antibodies, to proteolytic environments is disclosed. In one form of the invention the drug delivery system is a composition which comprises a porous substrate and an antibody bound to the substrate. In one embodiment, the composition comprises nanoporous silicon and can be used to deliver antibodies for the treatment, or for improving the repair, of a wound.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 47/52 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé inorganique, p. ex. un ion inorganique complexé avec l’ingrédient actif
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61L 15/32 - Protéines, polypeptidesLeurs produits de dégradation ou leurs dérivés, p. ex. albumine, collagène, fibrine, gélatine
A61L 15/42 - Utilisation de matériaux caractérisés par leur fonction ou leurs propriétés physiques
Methods for detecting a prostate cancer in a subject comprise detecting a marker selected from an endosomal associated marker and/or a lysosomal associated marker from the subject.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
69.
COMPOSITIONS AND MATERIALS FOR ASSISTING IN WOUND HEALING
A wound dressing comprising an oxygen-loaded zeolite. The oxygen-loaded zeolite releases oxygen when in use. Methods of producing an oxygen-loaded zeolite layer for the wound dressing and uses of the wound dressing are also disclosed.
A61L 15/18 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p. ex. serviettes hygiéniques, tampons contenant des matériaux inorganiques
A61L 15/22 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p. ex. serviettes hygiéniques, tampons contenant des matériaux macromoléculaires
C01B 39/02 - Zéolites aluminosilicates cristallinesLeurs composés isomorphesLeur préparation directeLeur préparation à partir d'un mélange réactionnel contenant une zéolite cristalline d'un autre type, ou à partir de réactants préformésLeur post-traitement
70.
APPARATUS AND METHOD FOR ANION DETECTION AND/OR MEASUREMENT
An apparatus for selectively detecting an anion in a medium and/or selectively measuring the concentration of an anion in a medium. The apparatus comprises at least one sensor and a conductive polymer film and is configured such that dielectric and/or electric property changes of the conductive polymer film can be detected by the sensor when the conductive polymer film is in hydraulic contact with the medium or after it has been in hydraulic contact with the medium. Methods of selectively detecting an anion in a medium and/or selectively determining a concentration of an anion in a medium are also provided.
G01N 27/22 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la capacité
G01N 27/12 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de l'absorption d'un fluideRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de la réaction avec un fluide
A dry composition, comprising three-dimensional porous microparticles, wherein the microparticles comprise: (i) an active substance (eg a poorly water soluble drug), (ii) polymeric nanoparticles such as those composed of a biocompatible and/or biodegradable polymer (eg a PLGA polymer) (iii) lipid droplets (eg droplets of a medium chain triglyceride (MCT)), (iv) a nanoparticle stabilizing agent such as PVA or DMAB, and optionally, (v) a cryoprotectant (eg mannitol); wherein said active substance is carried by said nanoparticles and/or lipid droplets. The composition of the present invention may be formulated into, for example, a medicament for the treatment and/or prevention of various diseases or disorders (eg human or veterinary therapeutics). The average diameter of the individual microparticles of the composition, may be in the order of 2.5-3.5 μm which are particularly suitable for administration to the lung.
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
The present disclosure relates to methods and products for imaging or labelling cells. Certain embodiments of the present disclosure provide a method of intracellular imaging of a cell. The method comprises exposing the cell to a complex comprising a phenylpyridine iridium (III) (and/or a functional derivative thereof) and a tetrazolato compound and imaging the complex in the cell.
The disclosure relates to a method of producing induced beta cells from urine-derived cells, the method comprising providing urine-derived cells; inducing the urine-derived cells by culturing said urine-derived cells in a primary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a first period of time to obtain induced endoderm cells; inducing the induced endoderm cells by culturing said induced endoderm cells in a secondary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a second period of time to obtain induced pancreatic precursor cells; and inducing the induced pancreatic precursor cells by culturing said pancreatic precursor cells in a tertiary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a third period of time to obtain induced beta cells.
The present disclosure relates to a heat exchanger system, and to a method of operation of the same. In one aspect, there is provided a heat exchanger system comprising a recuperator type heat exchanger exchanging heat between a first, flowing fluid, and a second fluid, and a means for reversing the flow direction of the flowing fluid repeatedly. In one form, the second fluid is flowing, and the heat exchanger system further comprises a means for reversing the flow direction of the second fluid frequently. An enhancement of heat transfer effectiveness has been found to be up to 30% due to flow reversal, depending on different factors, including the configuration of the heat exchanger, the thermo-physical properties of the fluids involved in the heat exchanger, and the temperature difference between hot and cold media, ΔT=Th-Tc.
F28D 7/00 - Appareils échangeurs de chaleur comportant des ensembles de canalisations tubulaires fixes pour les deux sources de potentiel calorifique, ces sources étant en contact chacune avec un côté de la paroi d'une canalisation
F28F 13/06 - Dispositions pour modifier le transfert de chaleur, p. ex. accroissement, diminution en affectant le mode d'écoulement des sources de potentiel calorifique
F28F 27/02 - Commandes ou dispositifs de sécurité spécialement adaptés pour les appareils d'échange ou de transfert de chaleur pour commander la répartition des sources de potentiel calorifique entre des canaux différents
F28F 3/00 - Éléments en forme de plaques ou de laminésEnsembles d'éléments en forme de plaques ou de laminés
F28D 9/00 - Appareils échangeurs de chaleur comportant des ensembles de canalisations fixes en forme de plaques ou de laminés pour les deux sources de potentiel calorifique, ces sources étant en contact chacune avec un côté de la paroi d'une canalisation
75.
Modulators of 14-3-3 functionality and uses thereof
Central Adelaide Local Health Network Inc. (Australie)
Inventeur(s)
Woodcock, Joanna
Lopez, Angel
Pitson, Stuart Maxwell
Samuel, Michael Susithiran
Coolen, Carl
Abrégé
The present disclosure relates to modulators of 14-3-3 functionality and their use in methods and compositions for preventing and/or treating various diseases, conditions and states, such as cancer and healing of wounds. Certain embodiments of the present disclosure provide a method of preventing and/or treating a disease, condition or state in a subject associated with altered 14-3-3 protein functionality and/or which would benefit from altering 14-3-3 functionality, the method comprising administering to the subject an effective amount of an agent which inhibits dimerization of the 14-3-3 protein, thereby preventing and/or treating the disease, condition or state in the subject.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A microfluidic device for measuring an amount of an oxidant in a solution is disclosed. The device comprises: a microfluidic substrate configured to mix a solution sample to be analysed with an indicator dye solution containing an indicator dye under conditions suitable for some of the indicator dye to react with any oxidant in the solution to produce an oxidant measurement solution having a reduced indicator dye concentration that is indicative of the amount of oxidant in the solution, the microfluidic substrate comprising an optical reading window through which the reduced indicator dye concentration in the oxidant measurement solution can be measured optically.
G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
The present disclosure relates to medical devices using coated polymers, methods for reducing platelet attachment and/or fouling associated with medical devices, and methods for coating polymers. Certain embodiments of the present disclosure provide a medical device comprising one or more polymeric materials coated with a hyperbranched polyglycerol.
A teleconferencing system for providing remote assistance comprises a local user apparatus that captures both the field of view of the local user along with physiological state of the local user, and a remote user apparatus to allow the remote user to view what the local user is seeing and doing. The local user and remote user have a shared view and a shared audio link, and the remote user can provided assistance to the local user in performing tasks at the local site. Additionally the physiological state of the local user is monitored, and from the physiological state data, an estimate of the emotional state or physiological state of the local user is provided to the remote user. The remote user can interact or assist the local user, including controlling the amount and/or type of assistance provided to the local user based on their current emotional state.
A61B 3/113 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G02B 27/00 - Systèmes ou appareils optiques non prévus dans aucun des groupes ,
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
79.
Processes for the selective separation of iron and aluminium
This disclosure relates to a process for selectively extracting Fe(III) ions from an aqueous feedstock containing Fe(III) ions and non-ferric ions. The process comprises contacting the feedstock with an organic phase comprising a phosphonium salt or ammonium salt ionic liquid under liquid-liquid extraction conditions for a time sufficient to allow transfer of at least some of the Fe(III) ions from the feedstock to the organic phase to provide an Fe(III) ion laden organic phase and an Fe(III) depleted feedstock, and separating the Fe(III) ion laden organic phase from the Fe(III) depleted feedstock.
C22B 3/00 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés
C22B 3/26 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par extraction liquide-liquide utilisant des composés organiques
CENTRAL ADELAIDE LOCAL HEALTH NETWORK INCORPORATED (Australie)
Inventeur(s)
Flynn, Bernard Luke
Aurelio, Luigi
Scullino, Carmen Vittoria
Wang, Bing Hui
Pitson, Stuart Maxwell
Pitman, Melissa Rose
Abrégé
The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosure further relates to the use of such compounds as research tools, use in therapy, to compositions and agents comprising said compounds, and to methods of treatment using said compounds.
C07D 271/113 - Oxadiazoles-1, 3, 4Oxadiazoles-1, 3, 4 hydrogénés avec des atomes d'oxygène, de soufre ou d'azote, liés directement aux atomes de carbone du cycle, les atomes d'azote ne faisant pas partie d'un radical nitro
C07D 419/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote, d'oxygène et de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 271/07 - Oxadiazoles-1, 2, 4Oxadiazoles-1, 2, 4 hydrogénés avec des atomes d'oxygène, de soufre ou d'azote, liés directement aux atomes de carbone du cycle, les atomes d'azote ne faisant pas partie d'un radical nitro
C07D 277/56 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 271/107 - Oxadiazoles-1, 3, 4Oxadiazoles-1, 3, 4 hydrogénés avec deux radicaux aryle ou aryle substitués liés en positions 2 et 5
A microfluidic chip suitable for use in liquid-liquid or liquid-gas phase transfer applications is disclosed. The microfluidic chip comprises a contact zone comprising a high aspect ratio channel in fluid connection with at least one liquid or gas inlet whereby, in use, at least two immiscible or partially immiscible liquid and/or gas streams exiting the at least one liquid or gas inlet flow adjacent one another and in contact with one another through the contact zone under conditions to allow transfer of at least some of a chemical entity from one stream to the other before the streams exit the high aspect ratio channel at a microchip outlet.
FLINDERS UNIVERSITY OF SOUTH AUSTRALIA (Australie)
UNIVERSITY OF CANTERBURY (Nouvelle‑Zélande)
UNIVERSITY OF SOUTH AUSTRALIA (Australie)
Inventeur(s)
Metha, Gregory F.
Andersson, Gunther
Golovko, Vladimir
Nann, Thomas
Abrégé
A method for the production of hydrocarbon(s), such as methane, or substituted hydrocarbons, such as methanol, the method comprising the steps of contacting a first catalyst with water in order to photocatalyse the splitting of at least some of the water into hydrogen and oxygen; and contacting a second catalyst with a gas stream comprising carbon dioxide and at least some of the hydrogen produced from step (a) in order to photocatalyse the reaction between the hydrogen and carbon dioxide to produce hydrocarbon(s), such as methane, and/or substituted hydrocarbons, such as methanol. In an embodiment, the catalyst comprises gold and or ruthenium nanoclusters supported on a substrate.
B01J 23/46 - Ruthénium, rhodium, osmium ou iridium
C10G 2/00 - Production de mélanges liquides d'hydrocarbures de composition non définie à partir d'oxydes de carbone
C07C 1/02 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir d'oxydes de carbone
C07C 1/12 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir d'oxydes de carbone à partir d'anhydride carbonique avec de l'hydrogène
83.
PLASMA POLYMERISED OXAZOLINE COATINGS AND USES THEREOF
A plasma polymerised polyoxazoline polymer is disclosed. Also disclosed is a substrate comprising a plasma polymerised polyoxazoline polymer film on a surface thereof, a process for preparing a plasma polymerised polyoxazoline polymer film on a surface of a substrate, a substrate comprising an antibiofouling surface, a substrate comprising a plasma polymerised polyoxazoline polymer film on a surface thereof and one or more ligands and/or biomolecules bonded to the polyoxazoline polymer film, and a process for immobilising a biomolecule on a surface of a substrate.
C08G 73/06 - Polycondensats possédant des hétérocycles contenant de l'azote dans la chaîne principale de la macromoléculePolyhydrazidesPolyamide-acides ou précurseurs similaires de polyimides
CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC. (Australie)
Inventeur(s)
Lopez, Angel, F.
Bonder, Claudine, S.
Thompson, Emma
Abrégé
A method of treating or preventing breast cancer (eg invasive ductal carcinoma) and/or cancer associated with elevated levels of either one or both of the IL-3 receptor (IL-3R) and interleukin-3 (IL-3) is discl osed which comprises administering to a subject an IL-3 -inhibiting agent such as an agent which inhibits (eg by blocking) IL-3R.
A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias. The inhibitors have the general structure I:
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
The present disclosure relates to complexes for intracellular imaging and also to methods and kits for intracellular imaging or cell labelling. Certain embodiments of the present disclosure provide a complex comprising a transition metal carbonyl compound, a conjugated bidentate ligand and a tetrazolato compound comprising a saccharide group.
The present invention relates to decorative coatings for plastic substrates, the decorative coatings ideally being stable and durable coatings that are spectrally tunable to permit the selection of a variety of appearances, and ideally providing a decorative metal finish. More particularly the present invention provides for a plastic substrate having a decorative coating including a spectrally controlling system and a stress controlling system. The spectrally controlling system includes alternating absorbing layers and transparent layers, and the stress controlling system controls the overall residual stress of the decorative coating to within a desired range. Further provided are methods for applying to a plastic substrate a decorative coating having a spectrally controlling system and a stress controlling system.
B05D 1/30 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces par gravité uniquement
B05D 1/02 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces réalisés par pulvérisation
B05D 1/18 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces par immersion
C09D 5/00 - Compositions de revêtement, p. ex. peintures, vernis ou vernis-laques, caractérisées par leur nature physique ou par les effets produitsApprêts en pâte
C09D 1/00 - Compositions de revêtement, p. ex. peintures, vernis ou vernis-laques, à base de substances inorganiques
B05D 5/06 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces pour obtenir des effets, finis ou des structures de surface particuliers pour obtenir des effets multicolores ou d'autres effets optiques
B05D 7/02 - Procédés, autres que le flocage, spécialement adaptés pour appliquer des liquides ou d'autres matériaux fluides, à des surfaces particulières, ou pour appliquer des liquides ou d'autres matériaux fluides particuliers à des substances macromoléculaires, p. ex. à du caoutchouc
Disclosed is a magnetic sensor for measuring flux density. The sensor comprises at least one tunnelling magnetoresistor, supporting circuitry and an output for outputting a signal from the tunnelling magnetoresistor. In another aspect, there is also provided a sensor probe comprising at least one magnetic sensor. A magnetic probe system is also described, comprising the probe sensor and processing circuitry. Methods of processing the output signal from the magnetic sensor are also described. In one application, the system and method allow for detection of tissue such as lymph nodes that have taken up small quantities of magnetic particles upon injection of a magnetic tracer containing the magnetic particles into a patient, and can be used to identify such tissue that could be affected by certain forms of cancer.
G01R 33/09 - Mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques en utilisant des dispositifs galvano-magnétiques des dispositifs magnéto-résistifs
G01R 33/12 - Mesure de propriétés magnétiques des articles ou échantillons de solides ou de fluides
89.
COMPOSITIONS AND METHODS FOR ADMINISTERING ANTIBODIES
The present invention relates to a drug delivery system and uses thereof. Specifically, a system that can be used to deliver therapeutic proteins, including antibodies, to proteolytic environments is disclosed. In one form of the invention the drug delievery system is a composition which comprises a porous substrate and an antibody bound to the substrate. In one embodiment, the composition comprises nanoporous silicon and can be used to deliver antibodies for the treatment, or for improving the repair, of a wound.
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
90.
DRUG DELIVERY COMPOSITION COMPRISING POLYMER-LIPID HYBRID MICROPARTICLES
A dry composition, comprising three-dimensional porous microparticles, wherein the microparticles comprise: (i) an active substance (eg a poorly water soluble drug), (ii) polymeric nanoparticles such as those composed of a biocompatible and/or biodegradable polymer (eg a PLGA polymer) (iii) lipid droplets (eg droplets of a medium chain triglyceride (MCT)), (iv) a nanoparticle stabilising agent such as PVA or DMAB, and optionally, (v) a cryoprotectant (eg mannitol); wherein said active substance is carried by said nanoparticles and/or lipid droplets. The composition of the present invention may be formulated into, for example, a medicament for the treatment and/or prevention of various diseases or disorders (eg human or veterinary therapeutics). The average diameter of the individual microparticles of the composition, may be in the order of 2.5-3.5 μm which are particularly suitable for administration to the lung.
Methods and compositions for delaying the onset of menopause and/or slowing the rate of loss of ovarian reserve are disclosed. The methods may involve administering a therapeutically effective amount of beta-cryptoxanthin (bCX) or a pharmaceutically acceptable salt, solvate or prodrug thereof to a female subject. The bCX may be administered in combination with a contraceptive agent and/or a multivitamin agent.
A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
92.
REMOTE PROGRAMMATIC FORENSIC DATA COLLECTION METHOD AND SYSTEM
A method for collection of digital forensic evidence from a target entity such as a computing device or software service such as a cloud service is described. The method includes identifying one or more remote interfaces for a target digital device or software service and then selecting a plurality of data collection functions provided by the one or more remote interfaces. The forensic soundness of the plurality of collection functions is determined and collection functions are partitioned into a priority one set which pass a first forensic soundness threshold, a priority two set that pass a second forensic soundness threshold, and a discard set. The execution order of the collection functions is determined based on the priority one set and the priority two set. A programmatic interface to the target digital device or software service is then developed such that in use the programmatic interface will executes the collection functions in the priority one set and the priority two set in the determined execution order to obtain data from first target device or service for forensic analysis. Programmatic interfaces can be generated for a range of digital devices or software service to generate a library of programmatic interfaces that can then be used by a wider less skilled user base to collect digital forensic data.
A data reduction method and tool for collection of digital forensic data from a target source is described. A target data source is forensically accessed and the files are filtered to generate a first set of files to be added to a data container. These files are further processed to create representations of the original files with reduced file sizes. Video files are converted into composite image files in which each image file comprises a plurality of frames sampled from the video file, and image files are converted into a standard format and size in order. The target data source is also processed to identify hidden data. The processed files are added to the data container using a compressed container format. Additionally a report is generated on all files, together with hard disk drive and partition information which can be reviewed by a practitioner. The method can be performed in parallel or subsequent to collection of a full forensic bit- for-bit copy and enables rapid collection, processing, indexing and searching of subset data to take place, which can quickly highlight devices that contain potential evidential material that may require full imaging and analysis, as well as devices for which full analysis may not be required.
The disclosure relates to a method of producing induced beta cells from urine-derived cells, the method comprising providing urine-derived cells; inducing the urine-derived cells by culturing said urine-derived cells in a primary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a first period of time to obtain induced endoderm cells; inducing the induced endoderm cells by culturing said induced endoderm cells in a secondary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a second period of time to obtain induced pancreatic precursor cells; and inducing the induced pancreatic precursor cells by culturing said pancreatic precursor cells in a tertiary induction culture medium comprising an effective amount of at least one small molecule reprogramming factor(s) for a third period of time to obtain induced beta cells.
A cuvette for optical spectroscopy comprising a substrate and a wicking structure in a spectral region on the substrate, the wicking structure comprising an array of pillars extending from a planar surface of the substrate with each pillar in the array being of substantially equal height in the spectral region, the wicking structure configured such that interpillar spacings between adjacent pillars in the spectral region are filled with an analyte solution when the solution is placed in contact with part of the wicking structure to thereby form a spectral sample of the analyte solution in the interpillar spacings that is suitable for optical spectroscopy.
G01N 21/00 - Recherche ou analyse des matériaux par l'utilisation de moyens optiques, c.-à-d. en utilisant des ondes submillimétriques, de la lumière infrarouge, visible ou ultraviolette
B05D 5/06 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces pour obtenir des effets, finis ou des structures de surface particuliers pour obtenir des effets multicolores ou d'autres effets optiques
Methods and apparatus for communication between terminals and an access node in a multiuser multicarrier communications network are described. The access node may be a satellite access node. Terminals are configured to perform initial estimation and tracking of channel offsets and to estimate channel offsets for future packets to be transmitted by the terminal. In some embodiments the channel offsets comprise mobility related channel offsets due to the relative movement between the access node and the plurality of terminals. Transmissions from the terminals to the access node are pre-compensated for the channel offsets, so that the aggregate signal received by the access node occupies a bandwidth greater or equal to the maximum signal bandwidth of any individual terminal. Terminal transmissions may overlap in frequency and time on the ground, but arrive orthogonally at the access node.
A method for enabling indoor positioning of a mobile receiver, including: detecting an orientation of the mobile receiver; measuring light intensities using at least three effective visible light receiving areas positioned on the mobile receiver, wherein the at least three effective visible light receiving areas are orientated such that a measurement of light intensity of a light from the same light source by each of the at least three effective visible light receiving areas is different from the others; and producing an output which enables a 3-dimensional indoor positioning of the mobile receiver relative to a second coordinate system.
G01S 1/70 - Radiophares ou systèmes de balisage émettant des signaux ayant une ou des caractéristiques pouvant être détectées par des récepteurs non directionnels et définissant des directions, situations ou lignes de position déterminées par rapport aux émetteurs de radiophareRécepteurs travaillant avec ces systèmes utilisant des ondes électromagnétiques autres que les ondes radio
G01S 5/16 - Localisation par coordination de plusieurs déterminations de direction ou de ligne de positionLocalisation par coordination de plusieurs déterminations de distance utilisant des ondes électromagnétiques autres que les ondes radio
G01S 7/481 - Caractéristiques de structure, p. ex. agencements d'éléments optiques
G01S 17/06 - Systèmes déterminant les données relatives à la position d'une cible
The present disclosure relates to methods and products for labelling, binding and/or detection of lipids. Certain embodiments provide a method of labelling a lipid. The method comprises exposing the lipid to a complex comprising a transition metal carbonyl compound, a conjugated bidentate ligand and a tetrazolato compound, and thereby labelling the lipid by binding the complex to the lipid.
G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C07D 257/10 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
C07F 7/00 - Composés contenant des éléments des groupes 4 ou 14 du tableau périodique
C07F 9/00 - Composés contenant des éléments des groupes 5 ou 15 du tableau périodique
C07F 11/00 - Composés contenant des éléments des groupes 6 ou 16 du tableau périodique
C07F 13/00 - Composés contenant des éléments des groupes 7 ou 17 du tableau périodique
C07F 15/00 - Composés contenant des éléments des groupes 8, 9, 10 ou 18 du tableau périodique
99.
DETECTING SEQUENCE MUTATIONS IN LEUKAEMIC FUSION GENES
CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC. (Australie)
Inventeur(s)
Parker, Wendy Tara
Yeung, David Tak On
Branford, Susan
Scott, Hamish Steele
Geoghegan, Joel Micah
Schreiber, Andreas Wolfgang
Abrégé
Methods of detecting mutations, particularly rare sequence mutations, within the kinase domain (KD) of a fusion gene comprising ABL1 are disclosed. These methods involve the use of a novel technique, termed Single Molecule Consensus Sequencing (SMCS). The methods particularly enable the detection of compound mutations present on the same BCR-ABL1 polynucleotide molecule that may be causative of an altered activity of an encoded protein, polypeptide or protein domain, which may in turn, be the cause of chronic myeloid leukaemia (CML) or acute lymphoblastic leukaemia (ALL) disease or, otherwise, of some disease- or treatment -associated characteristic (eg disease stage or drug resistance).
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une transférase
100.
Method and system for information integration in industrial systems
A computational method for performing a data transformation process for use in Engineering Asset Management on an industrial scale is described, The method and associated integration environment includes a transformation engine or module to map model elements and data items from a first information system, for example a procurement and construction database that records the thousands of individual components used to construct an industrial site, to a second information system. Such as an operation and maintenance database. The method uses a model transformation user interface using hierarchically linked layers to allow users to create, view and modify the transformation specification, as well as element terms and element relationships which define a transformation specification, without having to write the underlying code that performs the transformation.
